IPO Comments on the Updated EPO Guidelines for Examination
IPO Comments on the Updated EPO Guidelines for Examination
IPO Comments on the Updated EPO Guidelines for Examination
IPO Testimony to U.S. ITC Regarding COVID-19 Diagnostics and Therapeutics: [...]
IPO Response to Questions Re: USTR 2023 Special 301 Review
IPO Comments to CNIPA on Draft Amendment to the Trademark [...]
IPO’s Comments on the Draft 2022-2026 USPTO Strategic Plan
IPO Comments on Joint USPTO–FDA Collaboration Initiatives
IPO Comments Regarding USPTO Initiatives To Ensure the Robustness and [...]
IPO Comments Regarding Expanding Opportunities to Appear Before the Patent [...]
IPO Comments Regarding Expanding Admission Criteria for Registration to Practice [...]
IPO 2023 Special 301 Review Comments